AI agents are digital assistants based on a prompt. They reason through and break down problems into multi-step plans. They use the proper tools, work with other agents, and use context from memory to properly execute the job on NVIDIA accelerated systems.It starts with a simple prompt. Let's ask Perplexity to help start a food truck in Paris. First, the perplexity agent reasons through the prompt and forms a plan.Then calls other agents to help tackle each step using many tools. The market researcher reads ...

教育部网站6月11日发布《关于拟同意设置本科高等学校的公示》。其中包括"设立大湾区大学"。 据大湾区大学（筹）官网介绍，筹建大湾区大学是贯彻落实《粤港澳大湾区发展规划纲要》的重大战略 举措。大湾区大学是由广东省人民政府举办、东莞市政府投入保障为主的公办普通高等学校。学校立足 粤港澳大湾区，面向全中国，辐射全世界，以理工为主、精理强工，致力于办成一所"国际水准、开放 包容、湾区特色"，能引领未来科技发展、产业升级和社会进步的新型研究型大学。 学校开展全日制本科和研究生教育，形成本硕博贯通式培养体系，预计2030年达到在校生10000人左 右，本科生与研究生规模比例预计达1：1左右。 在学生培养方面，针对本科生，首批设置数学与应用数学、物理学、计算机科学与技术、材料科学与工 程和工业工程等5个本科专业，实行大类招生，分类培养，并对理学和工学等学科门类制定差异化的人 才培养方案。 松山湖校区主要建设与综合性国家科学中心有关的大科学装置、新型研发机构融合办学的学科领域，设 立相关领域研究院和科研平台，同时满足办学初期需求。 滨海湾校区同步启动，主要满足本科生和研究生培养、产学研合作和国际合作、创新创业孵化以及行政 办 ...

With just one subscription to Beyond the Wall Investing , you can save thousands of dollars a year on equity research reports from banks. You'll keep your finger on the pulse and have access to the latest and highest-quality analysis of this type of information.I initiated my coverage on Credo Technology Group Holding Ltd (NASDAQ: CRDO ) with a bullish rating in January 2025 , arguing that the CRDO stock's valuation — despite seemingly high multiples — isn't as expensive as many might haveHe leads the inves ...

Summary of PTC Therapeutics Conference Call Company Overview - **Company**: PTC Therapeutics - **Sector**: Biotechnology - **Key Executives**: Matt Klein (CEO), Pierre Grave (CFO) Key Points Industry and Company Performance - PTC Therapeutics is experiencing a pivotal year with strong execution across all areas of the company, following a successful 2024 [2][3] - The company has submitted four FDA New Drug Applications (NDAs), with one approval received and three pending, including the Suppiance NDA expected to be approved within six weeks [3] Financial Position - As of Q1, PTC Therapeutics has over $2 billion in cash, providing a solid foundation for planned product launches and R&D advancements [3] Product Pipeline and Launches - Upcoming products include Suppiance for PKU and potential approvals for Friedreich ataxia and Translarna in the U.S. [3][4] - The company is preparing for the launch of Suppiance in Europe, with an early access program already initiated in Germany [23][24] Translarna in Europe - Despite the lack of marketing authorization renewal, over half of European countries wish to continue commercializing Translarna, allowing PTC to maintain 25-30% of European revenue, which is about 40% of overall Translarna revenue for 2024 [7][8][10] Market Opportunity for Suppiance - Suppiance is positioned as a highly differentiated therapy for PKU, addressing a significant unmet need as only 10-15% of the estimated 15,000-17,000 patients in the U.S. are currently on existing therapies [12][13] - The company plans to price Suppiance at a premium to existing therapies, with payer support anticipated [13][14] Commercial Strategy - PTC has a well-established commercial team experienced in rare disease therapies, which will facilitate the launch of Suppiance [14] - The company has identified 103 PKU expert centers in the U.S., many of which overlap with existing treatment centers, aiding in the transition to new therapies [17][18] Friedreich Ataxia Program - Vatiquinone is positioned as a therapy for both pediatric and adult patients, with a significant market opportunity due to its safety and tolerability profile [39][40] - The company expects to target pediatric patients first, followed by adults who may have had issues with existing therapies [41][42] Regulatory and Clinical Development - The PDUFA date for vatiquinone is August 19, with positive feedback from the FDA regarding the absence of an AdCom meeting [49] - PTC518 for Huntington's disease has shown promising Phase II results, with plans for accelerated approval discussions based on the data [51][55] Cash Management and Future Plans - PTC Therapeutics has a strong cash position, allowing for flexibility in internal development and potential business development activities [66][67] - The company aims to reach $2 billion in top-line revenue, with significant contributions expected from PKU and Friedreich ataxia products [67][68] Conclusion - PTC Therapeutics is well-positioned for growth with a robust pipeline, strong financials, and a strategic approach to market entry and commercialization across its product offerings. The company is focused on addressing unmet needs in rare diseases while maintaining a solid cash position to support its initiatives.

Project Overview - The Galileo Project is a scientific endeavor aimed at exploring the possibility of extraterrestrial life, distinct from government investigations driven by national security concerns [5][30] - The project utilizes artificial intelligence to scan the sky for UAP, sharing all findings openly [1] - The project has established the first Galileo observatory, testing instruments with plans for hundreds of copies in multiple locations [7] Technology and Methodology - The project employs a network of cameras and specialized sensors recording the entire sky 24/7 [7] - AI software is built from scratch to filter out known objects and identify anomalies [8] - Instrumentation monitors the entire electromagnetic spectrum, focusing on objects within the atmosphere [18] - Over five months, approximately half a million objects were collected and reconstructed with a 95% confidence level [24] UAP and National Security - The US government released a report confirming over 140 sightings of unidentified aerial phenomena in 2021 [3] - Congress has elevated UAP to a top national security concern, with sightings being routine but under-reported [26] - The US Department of Defense announced the Gremlin Project, similar to The Galileo Project but closed source [28] Scientific and Academic Perspective - The Galileo Project seeks to bring scientific rigor to UAP research, challenging the stigma and promoting open investigation [14][25] - The project is open source, publishing all findings in peer-reviewed papers [29][30]

论文第一作者为何浩然，香港科技大学二年级博士，他的研究方向包括强化学习、生成流模型（GFlowNets）以及具身智能，通讯作者为香港科技大学电子与计算 机工程系、计算机科学与工程系助理教授潘玲。 测试时扩展（Test-Time Scaling）极大提升了大语言模型的性能，涌现出了如 OpenAI o 系列模型和 DeepSeek R1 等众多爆款。那么，什么是视觉领域的 test-time scaling？又该如何定义？ 为了回答这一问题，最近 香港科技大学 联合 快手可灵团队 推出 Evolutionary Search （EvoSearch） 方法，通过提高推理时的计算量来大幅提升模型的生成质 量，支持图像和视频生成，支持目前最先进的 diffusion-based 和 flow-based 模型。EvoSearch 无需训练，无需梯度更新，即可在一系列任务上取得显著最优效果， 并且表现出良好的 scaling up 能力、鲁棒性和泛化性。 随着测试时计算量提升，EvoSearch 表明 SD2.1 和 Flux.1-dev 也有潜力媲美甚至超过 GPT4o。对于视频生成，Wan 1.3B 也能超过 Wa ...

Core Insights - Ascentage Pharma announced that 13 studies of its key assets will be presented at the 2025 European Hematology Association Annual Congress in Milan, Italy, from June 12-15, 2025 [1][2] Group 1: Company Overview - Ascentage Pharma is a global biopharmaceutical company focused on addressing unmet medical needs in cancers, with a rich pipeline of innovative drug candidates [9] - The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for specific types of chronic myeloid leukemia (CML) [10] - The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor for treating various hematologic malignancies, with an NDA accepted for priority review in China [11] Group 2: Research Presentations - The congress will feature an oral presentation on integrating genomic and transcriptomic insights for predicting responses in patients with chronic myeloid leukemia (CML) [3] - Multiple poster presentations will include studies on the combination of olverembatinib with other therapies for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [4][5] - Online publications will cover various studies, including the efficacy and safety of olverembatinib in relapsed and persistent minimal residual disease positive Ph+ ALL patients [6][8]

Group 1 - The service Beyond the Wall Investing offers significant savings on equity research reports, potentially saving thousands of dollars annually for subscribers [1] - The investing group provides a fundamentals-based portfolio, weekly insights from institutional investors, and alerts for short-term trade ideas based on technical signals [2] - Community engagement is facilitated through ticker feedback requests and chat features, enhancing the overall investment experience [2] Group 2 - The article emphasizes that past performance does not guarantee future results, highlighting the importance of independent analysis [3] - It clarifies that no specific investment recommendations are provided, and opinions expressed may not represent the views of the entire platform [3] - The authors of the analysis may include both professional and individual investors, indicating a diverse range of perspectives [3]

Astrada Advisors delivers actionable recommendations that enhance portfolio performance and uncover alpha opportunities, supported by a strong track record in investment research at leading global investment banks. With expertise spanning technology, media, internet, and consumer sectors in North America and Asia, Astrada Advisors excels in identifying high-potential investments and navigating complex industries.Leveraging extensive local and global experience, Astrada Advisors offers a unique perspective o ...

Core Insights - Abeona Therapeutics has received FDA approval for its product pz-cel, which is a significant milestone for the company [1] - Prior to this approval, the company was assigned a Hold rating due to uncertainties surrounding its prospects [1] - The focus is on small and microcap biopharmaceutical companies, where mispricing is often most intense and institutional attention is limited [1] Company Analysis - Abeona Therapeutics operates in the biopharmaceutical sector, specifically targeting clinical stage products [1] - The company is part of a market segment that is often overlooked by institutional investors, leading to potential mispricing opportunities [1] - The analyst team emphasizes the importance of clinical information and consists mainly of high-ranking Life Sciences students from top UK universities [1] Market Context - The investment landscape for small biopharmaceutical companies is characterized by a lack of accurate analyst coverage, often influenced by investment banks with vested interests [1] - Retail investors make up a significant portion of public ownership in these companies, which can lead to price movements based on immaterial information [1]